Allogene Therapeutics, Inc. (ALLO)

Market Cap	336.76M
Revenue (ttm)	22,000
Net Income (ttm)	-257.59M
Shares Out	217.26M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,977,121
Open	1.555
Previous Close	1.560
Day's Range	1.510 - 1.690
52-Week Range	1.320 - 4.450
Beta	1.02
Analysts	Strong Buy
Price Target	9.66 (+523.23%)
Earnings Date	Mar 13, 2025

About ALLO

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 11, 2018
• Employees: 229
• Stock Exchange: NASDAQ
• Ticker Symbol: ALLO
• Website: https://www.allogene.com

Financial Performance

In 2024, Allogene Therapeutics's revenue was $22,000, a decrease of -76.84% compared to the previous year's $95,000. Losses were -$257.59 million, -21.29% less than in 2023.

Analyst Forecast

According to 10 analysts, the average rating for ALLO stock is "Strong Buy." The 12-month stock price forecast is $9.66, which is an increase of 523.23% from the latest price.

Price Target

$9.66

(523.23% upside)

Analyst Consensus: Strong Buy